PILOT RANDOMIZED TRIAL OF A CROSS-DIAGNOSIS COLLABORATIVE CARE PROGRAM FOR PATIENTS WITH MOOD DISORDERS

BASELINE DEPRESSION LEVELS DO NOT AFFECT EFFICACY OF COGNITIVE-BEHAVIORAL SELF-HELP TREATMENT FOR INSOMNIA

n=198 mild depression scores scorebetween16
0=no problem-4=very severe problem total score range=0-28
alpha=0.79- 0.92; retest correlation is 0.90

THE MORE IT IS NEEDED, THE LESS IT IS WANTED: ATTITUDES TOWARD FACE-TO-FACE INTERVENTION AMONG DEPRESSED PATIENTS UNDERGOING ONLINE TREATMENT

EFFECT OF TRANSDIAGNOSTIC CBT FOR ANXIETY DISORDERS ON COMORBID DIAGNOSES

A BIOPSYCHOSOCIAL MODEL OF SOCIAL ANXIETY AND SUBSTANCE USE

VAL66MET BDNF GENOTYPES IN MELANCHOLIC DEPRESSION: EFFECTS ON BRAIN STRUCTURE AND TREATMENT OUTCOME

VENTROMEDIAL PREFRONTAL CORTEX REACTIVITY IS ALTERED IN GENERALIZED ANXIETY DISORDER DURING FEAR GENERALIZATION

gs 60% mixed model repeated measures anova

and 15 without comorbid major depression Mean age overall=22.3, SD=4.5
time TR=2100 ms, echo time TE=23 ms, flip angle=83◦, matrix=96*96

ACUTE STRESS DISORDER VERSUS CHRONIC POSTTRAUMATIC STRESS DISORDER: INHIBITION OF FEAR AS A FUNCTION OF TIME SINCE TRAUMA

YOUTH GENETIC VULNERABILITY TO MATERNAL DEPRESSIVE SYMPTOMS: 5-HTTLPR AS MODERATOR OF INTERGENERATIONAL TRANSMISSION EFFECTS IN A MULTIWAVE PROSPECTIVE STUDY

population stratification 39 restricted maximum likelihood estimation

ABERRANT AMYGDALA-FRONTAL CORTEX CONNECTIVITY DURING PERCEPTION OF FEARFUL FACES AND AT REST IN GENERALIZED SOCIAL ANXIETY DISORDER

EVIDENCE FOR DISTINCT GENETIC EFFECTS ASSOCIATED WITH RESPONSE TO 35% CO2

HIGHER IN VIVO SEROTONIN-1A BINDING IN POSTTRAUMATIC STRESS DISORDER: A PET STUDY WITH [11C]WAY-100635

zolpidem>7 days before scan no substance abusewithin2

ADCYAP1R1 GENOTYPE, POSTTRAUMATIC STRESS DISORDER, AND DEPRESSION AMONG WOMEN EXPOSED TO CHILDHOOD MALTREATMENT

IMPLICATIONS OF THE USE OF GENETIC TESTS IN PSYCHIATRY, WITH A FOCUS ON MAJOR DEPRESSIVE DISORDER: A REVIEW

increasing accuracy of individual risk estimates
deficient problem solving coping 30 3 meta analysis
methodological inconsistencies of earlier meta analysis
updated august 2011 46 adtc genetic test
broader impact of molecular disease risk estimates
communicating dna based disease risk estimates
uncertainty of individual genetic risk estimates
commercial provision of dtc genetic test
validated genetic test marketed dtc within commercial test